Core Viewpoint - Recently, Hisco (002653) received approval from the Shenzhen Stock Exchange's Listing Review Center for its application to issue shares to specific investors [1] Group 1: Share Issuance Details - Hisco plans to issue no more than 70 million shares, which does not exceed 30% of the total share capital prior to this issuance [4] - The total amount of funds to be raised from this issuance is capped at 1,245.2567 million yuan, which will be used for new drug research and development projects and to supplement working capital [4] Group 2: Fund Allocation - The investment amount for the new drug research project is 965.2567 million yuan, while 280 million yuan will be allocated to supplement working capital [5] - The total amount of funds raised will be 1,245.2567 million yuan [5] Group 3: Strategic Importance - The company is currently in a critical phase of transitioning to innovative drugs, maintaining a high level of R&D investment, with R&D expenditures as a percentage of revenue reaching 31.87%, 26.09%, and 26.90% for the years 2022 to 2024 respectively [6] - The company has seen a continuous expansion in market share for its key products, with innovative drugs such as the injection of环泊酚 (Sishuning), the capsule of苯磺酸克利加巴林 (Simeining), and others being included in the medical insurance directory [6] - The implementation of this fundraising project is expected to accelerate the R&D process of innovative drugs, expanding the depth and breadth of the company's product pipeline, thereby laying a solid foundation for the commercialization of more products [6]

Core Viewpoint - Tianjin Pharmaceutical Industry is undergoing a strategic transformation from a "production-driven" model to a "dual empowerment of R&D and market" approach, as indicated by the company's recent organizational changes and focus on core business areas [2][3]. Group 1: Organizational Changes - In September 2023, Tianjin Pharmaceutical established two main centers for raw material manufacturing and sales, with additional centers for product planning and R&D set to launch in early 2024 [2]. - The company aims to optimize its organizational structure to adapt to new industry dynamics, reflecting a comprehensive strategic choice beyond merely rebranding [2]. Group 2: Focus on Core Areas - The company is concentrating on critical therapeutic areas such as emergency medicine, dermatology, ophthalmology, anesthetics, respiratory, and autoimmune diseases, based on thorough research into disease patterns and clinical needs [3]. - The raw material manufacturing center achieved a capacity utilization rate of 92% this month, showcasing operational efficiency [3]. Group 3: R&D Investment and Innovation - Over the past three years, the company has invested more than 150 million yuan annually in R&D, with the R&D expense ratio expected to rise to 7.7% in 2024 [4]. - The company has developed several products in dermatology and ophthalmology, including the domestically exclusive Difluprednate eye drops set to launch in 2025, utilizing new technology for better drug penetration [4][5]. Group 4: Internationalization Strategy - The company is pursuing an "integrated development of domestic and international sales" strategy, leveraging its advantages in raw material and formulation integration to achieve resource sharing and market synergy [5][6]. - Tianjin Pharmaceutical is transitioning from "product export" to "capability export," aiming to build a global supply chain and local production capacity in countries along the Belt and Road Initiative [6]. Group 5: Compliance and Long-term Stability - Compliance is emphasized as a fundamental principle for sustainable growth, with the company implementing a comprehensive compliance management system and ensuring that all key personnel sign compliance commitments [7]. - The company maintains a competitive edge in the steroid hormone sector, with over 80% self-sufficiency in key raw materials and numerous international certifications [7][8]. Group 6: Long-term Vision - The company views the pharmaceutical industry as a marathon rather than a sprint, focusing on deep specialization in steroids and long-term innovation to solidify its development foundation [8][9].

Group 1 - The company’s subsidiary, Tianjin Pharmaceutical Co., Ltd., has received a registration certificate from the Ministry of Health of the Republic of Panama for its injectable drug, Methylprednisolone Sodium Succinate, allowing it to produce and sell the product in the Panamanian market [1][2] - The drug is a corticosteroid used for anti-inflammatory treatment, immunosuppressive therapy, treatment of blood diseases and tumors, and shock treatment [1] - The global market sales for Methylprednisolone injectable products were reported to be $526 million in 2023 and $521 million in 2024 according to the IQVIA database [1] Group 2 - The registration of the drug is expected to create new opportunities for the company’s formulation business in the Panamanian market and further promote its international strategic layout [2] - The timeline for the drug's sales in foreign markets, market size, and subsequent expansion progress remains uncertain, influenced by external market conditions and exchange rate fluctuations [2]

Core Viewpoint - Tianjin Pharmaceutical Industry announced that its subsidiary, Tianjin Yaohe Pharmaceutical Co., Ltd., has received registration certification from the Ministry of Health of the Republic of Panama for its injectable methylprednisolone sodium succinate, allowing the company to produce and sell the product in the Panamanian market [1] Group 1 - The product is an injectable form of methylprednisolone sodium succinate [1] - The registration certification signifies a key milestone for the company in expanding its market presence in Panama [1] - This development may enhance the company's revenue potential through new market opportunities [1]

Core Viewpoint - Tianjin Pharmaceutical Industry Co., Ltd. (津药药业) announced that its subsidiary, Tianjin Yaohe Pharmaceutical Co., Ltd., has received a registration certificate from the Ministry of Health of the Republic of Panama for its injectable Methylprednisolone Acetate, allowing production and sales in the Panamanian market [1] Group 1 - The drug Methylprednisolone Acetate is a corticosteroid used for anti-inflammatory treatment, immunosuppressive therapy, treatment of blood diseases, tumors, and shock [1] - The registration application was submitted in 2024, and the certificate was received in November 2025 [1] - According to IQVIA data, the global market sales for Methylprednisolone injectable products were $526 million in 2023 and are projected to be $521 million in 2024 [1] Group 2 - The registration of Methylprednisolone Acetate in Panama presents new opportunities for the company's formulation business and further supports its international strategic layout [1]

Core Viewpoint - The company announced that its subsidiary, Tianyao Heping, has received registration certification from the Ministry of Health of the Republic of Panama for its injectable methylprednisolone sodium succinate (500mg freeze-dried powder injection), allowing for local production and sales [1] Group 1: Product Approval and Market Expansion - The approved drug is a corticosteroid used for anti-inflammatory treatments [1] - The registration application was submitted in 2024, and the certification was obtained in November 2025 [1] - The global sales figures for methylprednisolone injectable products are projected to be $526 million in 2023 and $521 million in 2024 [1] Group 2: Strategic Implications - This approval presents an opportunity for the company to expand its formulation business into the Panamanian market, enhancing its internationalization strategy [1] - However, there is uncertainty regarding the sales performance in this new market [1]

Core Viewpoint - Tianjin Pharmaceutical Co., Ltd. (600488.SH) announced that its subsidiary, Tianjin He Ping Pharmaceutical Co., Ltd., has received registration certification from the Ministry of Health of the Republic of Panama for its injectable Methylprednisolone Sodium Succinate, allowing the product to be produced and sold in the Panamanian market [1] Group 1 - The injectable Methylprednisolone Sodium Succinate is a corticosteroid medication primarily used for anti-inflammatory treatment, immunosuppressive therapy, treatment of blood diseases, tumor treatment, and shock treatment [1]

Group 1 - National Integrated Circuit Industry Fund plans to reduce its stake in Jiangbolong by no more than 4,159,815 shares, accounting for 1.00% of the total share capital, between May 27, 2025, and August 26, 2025 [1] - The reduction is due to the fund's operational management needs and will be executed through centralized bidding at market prices [1] - The implementation of this reduction plan will not lead to a change in the company's control or significantly impact its governance structure and ongoing operations [1] Group 2 - Haitai Weiye has received approval from the China Securities Regulatory Commission for its H-share issuance, planning to issue no more than 710.52 million overseas listed ordinary shares [2] - The listing will take place on the main board of the Hong Kong Stock Exchange, but the matter still carries uncertainties [2] Group 3 - Fudan Zhangjiang announced a price reduction of at least 35% for its Doxorubicin Liposome Injection starting May 1, 2025, which is expected to negatively impact sales revenue [3] - The drug generated approximately RMB 210 million in sales for the year 2024, representing 29% of the company's total sales revenue [3] - The price adjustment may lead to a risk of single product loss for the drug in 2025 [3] Group 4 - Xinyuan Technology's director expressed inability to guarantee the authenticity and completeness of the 2024 annual report and related financial documents, citing significant issues identified by the audit firm [4] - The company has received a notice of investigation from the securities regulatory authority, and the audit report issued was unable to express an opinion [4] Group 5 - ST Xinchao announced that its stock will be suspended from trading starting May 6, 2025, due to the inability to disclose the audited 2024 annual report and the 2025 Q1 report within the legal timeframe [5] - If the company fails to disclose the 2024 annual report within two months of the suspension, it will face delisting risk warnings [5] Group 6 - Huakang Clean has pre-won a project worth RMB 167 million [6] - Tongguang Cable has pre-won a procurement project from the State Grid valued at RMB 142 million [6] - Fengmao Co. has increased its investment in a production base in Thailand to RMB 26 million [6] Group 7 - Huaren Pharmaceutical's wholly-owned subsidiary has obtained a medical device registration certificate for wound dressings [7] Group 8 - Major shareholders of Kairun Co. plan to reduce their holdings by no more than 9 million shares [10] - CITIC Securities has completed its reduction plan for China Gold [10] - The reduction plan for Hengfeng Information's director and vice president has been completed [10]

Core Viewpoint - Tianjin Pharmaceutical Industry is recognized as a leading domestic manufacturer of steroid hormone drugs and a global leader in amino acid raw materials, showcasing its advanced position and demonstration effect in the industry for the year 2024 [1] Product Matrix - The company has a diverse product matrix with over 70 types of raw materials, including dexamethasone series, prednisone series, methylprednisolone series, betamethasone series, and amino acids, as well as more than 10 dosage forms such as injections, ointments, and tablets, catering to various patient treatment needs [2] R&D Innovation - In recent years, the company has significantly enhanced its product R&D and scientific research system, focusing on steroid hormones and amino acids, and implementing a "raw materials + formulations" full industry chain layout, with R&D investment reaching 248 million yuan in 2024, accounting for 7.7% of revenue, reflecting its strong R&D capabilities [3] Dual-Track Strategy - The company employs a dual-track strategy of "innovation line" and "generic line" to accelerate the new drug approval process, with 11 specifications of 10 products recently receiving approval, including the first domestic approval for a specific injection by its subsidiary [4] Market Performance - Among its products, the injection of isopropyl methochloride has shown strong market performance, with sales increasing from 756 million yuan in 2022 to 821 million yuan in 2023, and is expected to expand further due to its inclusion in the national medical insurance [5] - The inhalation solution of acetylcysteine is also a national medical insurance drug, with significant market potential in treating respiratory diseases, indicating a stable growth outlook as the patient population expands [5] Future Outlook - The company plans to continue its commitment to innovation, increasing investment in technology R&D, and focusing on new product development and consistency evaluation to provide high-quality, efficient drugs for patients and deliver substantial value returns to shareholders [6]